Payment overview · 2025
General Payments
$778.84
30 reported records · 11 companies
Healthcare provider profile · identity verified
Naresh P Menezes, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAND O LAKES, FL · NPI 1306814694
Verified facts
What the public records show
CMS Open Payments records show Naresh P Menezes, M.D. received $778.84 in general payments during 2025 across 30 reported records.
Organogenesis Inc. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Paxlovid.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $190.44 | 24.4% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $113.03 | 14.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.93 | 14.2% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $101.05 | 13.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.55 | 8.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.49 | 6.6% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $46.03 | 5.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $44.32 | 5.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.80 | 2.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.18 | 2.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.02 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $778.84 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NOVACHOR Normalized: novachor |
Medical Supply | Organogenesis Inc. | $155.77 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $113.03 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $68.48 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.49 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.49 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $46.03 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $44.79 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $44.62 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.45 | 2 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $34.67 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.82 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 29 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 812 | 260 |
| Losartan Potassium | Losartan Potassium | 710 | 210 |
| Levothyroxine Sodium | Levothyroxine Sodium | 575 | 164 |
| Alprazolam | Alprazolam | 505 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 440 | 135 |
| Lisinopril | Lisinopril | 365 | 110 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 294 | 50 |
| Metformin Hcl | Metformin Hcl | 270 | 79 |
| Gabapentin | Gabapentin | 240 | 82 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 234 | 34 |
| Simvastatin | Simvastatin | 221 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 69 |
| Tramadol Hcl | Tramadol Hcl | 209 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 61 |
| Trazodone Hcl | Trazodone Hcl | 203 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 70 |
| Glimepiride | Glimepiride | 189 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 53 |
| Omeprazole | Omeprazole | 179 | 63 |
| Oxycodone Hcl | Oxycodone Hcl | 174 | 18 |
| Celecoxib | Celecoxib | 166 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 166 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 58 |
| Montelukast Sodium | Montelukast Sodium | 154 | 48 |
| Allopurinol | Allopurinol | 149 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 61 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 147 | 99 |
| Furosemide | Furosemide | 144 | 51 |
| Famotidine | Famotidine | 138 | 51 |
| Sertraline Hcl | Sertraline Hcl | 131 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 37 |
| Cefdinir | Cefdinir | 126 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 38 |
| Temazepam | Temazepam | 111 | 19 |
| Alendronate Sodium | Alendronate Sodium | 108 | 38 |
| Lorazepam | Lorazepam | 108 | 16 |
| Azithromycin | Azithromycin | 107 | 90 |
| Clonazepam | Clonazepam | 96 | 12 |
| Atenolol | Atenolol | 94 | 25 |
| Potassium Chloride | Potassium Chloride | 94 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 30 |
| Prednisone | Prednisone | 90 | 56 |
| Memantine Hcl | Memantine Hcl | 87 | 30 |
| Metformin Hcl Er | Metformin Hcl | 87 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 25 |
| Carvedilol | Carvedilol | 79 | 24 |
| Finasteride | Finasteride | 76 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 15 |
| Propranolol Hcl | Propranolol Hcl | 69 | 21 |
| Eliquis | Apixaban | 68 | 20 |
| Pregabalin | Pregabalin | 67 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 12 |
| Warfarin Sodium | Warfarin Sodium | 62 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 23 |
| Ezetimibe | Ezetimibe | 60 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 59 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 29 |
| Lovastatin | Lovastatin | 56 | 16 |
| Ondansetron Odt | Ondansetron | 53 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 12 |
| Diazepam | Diazepam | 51 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 50 | 22 |
| Methocarbamol | Methocarbamol | 49 | 36 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Carisoprodol | Carisoprodol | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 45 | 14 |
| Meloxicam | Meloxicam | 44 | 28 |
| Fluconazole | Fluconazole | 43 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 16 |
| Baclofen | Baclofen | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 23 |
| Benazepril Hcl | Benazepril Hcl | 31 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | 22 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Amoxicillin | Amoxicillin | 30 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 17 |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Novolog | Insulin Aspart | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 13 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 15 |
| Metronidazole | Metronidazole | 24 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 11 |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 18 |
| Valsartan | Valsartan | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 18 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 17 | 17 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 17 | 17 |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 11 |
| Glipizide | Glipizide | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Xtampza Er | Oxycodone Myristate | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 13 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nucynta | Tapentadol Hcl | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $778.84 · 30 records | Organogenesis Inc. | ABRYSVO, AFFINITY, CAPVAXIVE, COMIRNATY, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, KISUNLA, Korlym, Leqembi, MOUNJARO, NOVACHOR, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error